Previous studies with cholinesterase inhibitors in patients with Alzheimer's Disease (AD), and the ongoing multi-center study of THA, suggests that a subgroup of patients with (AD) are responsive to this pharmacological intervention. However, a substantial proportion of patients are virtually unaffected by the administration of cholinesterase inhibitors. Data generated in animals with combined lesions of the nucleus basalis and locus coeruleus indicate that the addition of a locus coeruleus lesion to animals with nucleus basalis lesion completely eliminated responsivity to cholinomimetic agents. However the administration of the alpha II agonist clonidine, combined with a cholinomimetic, restores the ability of the cholinomimetic compound to reverse the poor performance associated with a nucleus basalis lesion. These data suggest that it is essential to the efficacy of a cholinergic compound that there be an intact central noradrenergic system. In addition these data constitute the foundation of a hypothesis proposing that some of the nonresponsivity to cholinomimetic agents, and the variable therapeutic effects observed following the administration of these compounds, may be a manifestation of variable noradrenergic degeneration in the AD brain. Specifically, those Alzheimer;s patients with a profound noradrenergic deficit would be anticipated to have no alleviation of symptoms following the administration of a cholinesterase inhibitor. In order to test this hypothesis a series of antemortem noradrenergic markers will be investigated for the possibility that they will be predictive of responsivity to the cholinesterase inhibitor THA alone combined with either clonidine, deprenyl, or desipramine. In a second parallel investigation the validity of these antemortem noradrenergic markers will be tested in a separate cohort of new stage Alzheimer;s patients whose antemortem parameters will be composed with the changes on post mortem examination in noradrenergic parameters when these same Alzheimer;s patients are autopsied.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
5P50AG005138-07
Application #
3809200
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
7
Fiscal Year
1990
Total Cost
Indirect Cost
Name
Mount Sinai School of Medicine
Department
Type
DUNS #
City
New York
State
NY
Country
United States
Zip Code
10029
Ki?emet-Piska?, Spomenka; Babi? Leko, Mirjana; Blažekovi?, Antonela et al. (2018) Evaluation of cerebrospinal fluid phosphorylated tau231 as a biomarker in the differential diagnosis of Alzheimer's disease and vascular dementia. CNS Neurosci Ther 24:734-740
Soleimani, Laili; Ravona-Springer, Ramit; Heymann, Anthony et al. (2018) Depression is more strongly associated with cognition in elderly women than men with type 2 diabetes. Int Psychogeriatr :1-5
Burke, Shanna L; Maramaldi, Peter; Cadet, Tamara et al. (2018) Decreasing hazards of Alzheimer's disease with the use of antidepressants: mitigating the risk of depression and apolipoprotein E. Int J Geriatr Psychiatry 33:200-211
Audrain, Mickael; Haure-Mirande, Jean-Vianney; Wang, Minghui et al. (2018) Integrative approach to sporadic Alzheimer's disease: deficiency of TYROBP in a tauopathy mouse model reduces C1q and normalizes clinical phenotype while increasing spread and state of phosphorylation of tau. Mol Psychiatry :
Boban, Mirta; Babi? Leko, Mirjana; Miški?, Terezija et al. (2018) Human neuroblastoma SH-SY5Y cells treated with okadaic acid express phosphorylated high molecular weight tau-immunoreactive protein species. J Neurosci Methods :
Zhu, Carolyn W; Grossman, Hillel; Neugroschl, Judith et al. (2018) A randomized, double-blind, placebo-controlled trial of resveratrol with glucose and malate (RGM) to slow the progression of Alzheimer's disease: A pilot study. Alzheimers Dement (N Y) 4:609-616
Qian, Winnie; Fischer, Corinne E; Schweizer, Tom A et al. (2018) Association Between Psychosis Phenotype and APOE Genotype on the Clinical Profiles of Alzheimer's Disease. Curr Alzheimer Res 15:187-194
Davis, Jeremy J (2018) Performance validity in older adults: Observed versus predicted false positive rates in relation to number of tests administered. J Clin Exp Neuropsychol 40:1013-1021
Gallagher, Damien; Kiss, Alex; Lanctot, Krista et al. (2018) Depression and Risk of Alzheimer Dementia: A Longitudinal Analysis to Determine Predictors of Increased Risk among Older Adults with Depression. Am J Geriatr Psychiatry 26:819-827
Silverman, Jeremy M; Schmeidler, James (2018) Outcome age-based prediction of successful cognitive aging by total cholesterol. Alzheimers Dement 14:952-960

Showing the most recent 10 out of 555 publications